Case Report

Eales’ Disease: When the Rare Sounds Frequent

Beatriz Oliveira Lopes,1 Margarida Sena Brízido,1 Ana Isabel Reis,2 Margarida Maria Miranda,1 and Susana Morais Pina1

1Department of Ophthalmology, Beatriz Ângelo Hospital, Loures, Portugal
2Department of Medicine, Beatriz Ângelo Hospital, Loures, Portugal

Correspondence should be addressed to Beatriz Oliveira Lopes; bibas.oliveiralopes@gmail.com

Received 14 April 2021; Accepted 22 July 2021; Published 10 August 2021

Academic Editor: Takaaki Hayashi

Copyright © 2021 Beatriz Oliveira Lopes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Eales’ disease is a peripheral occlusive retinal phlebitis, with an unclear pathogenesis. The classic association with hypersensitivity to Mycobacterium tuberculosis infers that immunologic disturbance may be involved. Here, we described three cases of Eales’ disease. All patients are Caucasian men aged 27-58 years and presented with vitreous hemorrhage and/or peripheral venous vasculitis. Tuberculin skin sensitive test (Mantoux screening test) and interferon-gamma release assay (IGRA) were positive in all patients. Therapeutic approach included antituberculosis therapy and systemic steroids, associated or not to immunosuppressive therapy, and retinal scatter photocoagulation in all cases. Antivascular endothelial grow factor (VEGF) intravitreal injections were also required in two cases. Since various retinal diseases can resemble this presentation, Eales’ disease is considered a diagnosis of exclusion. Early diagnosis and appropriate therapeutic approach are both essential to accomplish disease control and reduce ophthalmologic complications.

1. Introduction

Eales’ disease is a primary idiopathic peripheral obstructive retinal vasculopathy, reported in 1880 by Henry Eales for the first time [1]. A relation to ocular inflammation was described few years later [2, 3]. Healthy young men are the most affected by this disease, which is more prevalent in India and the Middle East [1]. In recent years, more cases affecting older adults have been described.

The clinical findings of Eales’ disease include perivascular phlebitis and secondary proliferative retinopathy with neovascularization, recurrent vitreous hemorrhages, and possible tractional retinal detachment [1, 2]. Other signs of ocular inflammation as vitritis and anterior chamber cell reaction may also be present. The clinical course of Eales’ disease is highly variable, presenting itself with gradual progression in few cases and temporary or even permanent remission in others [4].

Although the pathophysiology is poorly clarified, literature suggests that there is a clear association between Eales disease and Mycobacterium tuberculosis [2, 4, 5].

Different therapeutic approaches are suggested for Eales’ disease, depending on its clinical stage [3, 5]. The typical retinal vasculitis usually requires treatment with systemic steroids in combination with complete antituberculosis therapy for a minimal period of 9 months. Steroid-paring immunosuppressive agents, like methotrexate, cyclosporine, and azathioprine, are usually reserved for cases which corticosteroids are not sufficient, need to be discontinued, or are contraindicated. Peripheral retinal scatter photocoagulation and anti-VEGF intravitreal injections are also essential therapeutic approaches in cases of proliferative disease and important retinal ischemia [2, 5]. In case of secondary ocular complications such as tractional retinal detachment and/or persistent vitreous hemorrhage, pars plana vitrectomy surgery may improve visual prognosis [2].
2. Clinical Cases

2.1. Patient 1. A healthy 27-year-old Caucasian male presented with progressive blurred vision in the right eye (OD) (Table 1). He denied ocular pain, headaches, and other ocular or systemic symptoms. Best corrected visual acuity (BCVA) was 10/10 in both eyes. Anterior segment evaluation showed low-grade iridocyclitis in the OD. Dilated ocular fundus examination revealed mild vitritis, optic disc edema, vascular tortuosity, and venous vasculitis with perivascular hemorrhages mainly in the nasal quadrants of the OD (Figure 1). Fluorescein angiography showed severe venous vasculitis with important retinal ischemia in the corresponding quadrants of the same eye (Figure 1 and Table 1). Unilateral panuveitis with retinal vasculitis prompted for the search of an etiology study while topical therapy with prednisolone and bromofenac, was implemented.

Initial investigation included hemogram, platelet count, hepatic and renal function, erythrocyte sedimentation rate, human leukocyte antigen (HLA) B51, anticardiolipin antibody, lysozyme, angiotensin-converting enzyme (ACE), and infectious serologic analysis. No suspicious lesions indicating active tuberculosis or sarcoidosis were found in the computed tomography (CT) of the thorax; although, it showed a cisural micronodule with a 4 mm ganglion (Table 1). A further systematic review was unremarkable. Tuberculin skin sensitive test and IGRA test (5.59) were positive, and Eales’ disease was considered the likely diagnosis.

Besides topical therapy, corticoid therapy (1 mg/kg/day oral prednisolone) with slow progressive withdrawal was started, associated with quadruple antituberculosis therapy (ethambutol, rifampicin, pyrazinamide and isoniazid). Oral methotrexate (15 mg/week) was introduced two months later, keeping slow progressive corticosteroids withdrawal

| Case 1 | Case 2 | Case 3 |
|--------|--------|--------|
| **Sex** | Male | Male | Male |
| **Age (years)** | 27 | 49 | 58 |
| **Laterality** | Unilateral | Bilateral | Bilateral |
| **Clinical presentation** | Progressive blurred vision in the right eye | Acute bilateral decrease visual acuity and floaters | Floaters in the left eye over the previous 6 months |
| **Anterior segment evaluation** | Low-grade iridocyclitis | Unremarkable | Unremarkable |
| **Fundus features** | Vitritis, optic disc edema, venous vasculitis, and perivascular haemorrhages in nasal quadrants (OD) | Bilateral vitritis, vitreous hemorrhage, retinal vasculitis, hemorrhages in all retinal quadrants, and macular edema | Bilateral peripheral hemorrhages, vascular remodeling, neovascularization, vitreous hemorrhage, and macular edema (OS) |
| **Ophthalmology multimodal evaluation** | FA: venous vasculitis with retinal ischemia | FA: bilateral occlusive venous vasculitis with retinal ischemia | FA: bilateral venous vasculitis with peripheral ischemia, neovascularization |
| **Thorax TC** | Cisural micronodule with a 4 mm ganglion | Unspeciﬁc small bilateral hilar ganglia | Apical reticular pattern, residual fibrotic, and retracted changes |
| **Systemic evaluation** | Positive | Negative | Negative |
| **Systemic treatment** | Quadrupe antitubercular treatment, prednisolone (1 mg/kg/day) with progressive withdrawal, and methotrexate (20 mg/week) | Quadrupe antitubercular treatment, prednisolone (1 mg/kg/day) with progressive withdrawal, and methotrexate (20 mg/week) | Quadrupe antitubercular treatment and prednisolone (1 mg/kg/day) with progressive withdrawal |
| **Ocular treatment** | Topical prednisolone and bromofenac | Scatter laser photocoagulation and intravitreal anti-VEGF in both eyes | Scatter laser photocoagulation and intravitreal anti-VEGF in both eyes |
| **Time on follow-up** | 2 years | 2 years | 4 years |
| **Follow-up** | Clinically stable with no need for therapy | Clinically stable, under methotrexate (20 mg/week) and prednisolone (2.5 mg/day) | Clinically stable with no need for therapy |
| **Significant visual acuity recovery, restriction of visual field** | Significant visual acuity recovery | Significant visual acuity recovery |

**Table 1:** Description of the presented cases. Abbreviations: OD: right eye; OS: left eye; FA: fluorescein angiography; SD-OCT: spectral domain optical coherence tomography; ERM: epiretinal membrane; CME: cystoid macular edema; CT: computed tomography; IGRA: interferon-gamma release assay; VEGF: antivascular endothelial growth factor.
with clinical improvement (Table 1). Sectorial laser photocoagulation of the ischemic nasal quadrants of the retina was performed after vasculitis remission (Figure 1).

Two years after diagnosis, having completed one year of antitubercular and two years of immunosuppressive treatment, the patient remains clinically stable, with no signs of active vasculitis and no need for further therapy.

2.2. Patient 2. A healthy 48-year-old Caucasian male came to the emergency room with acute bilateral decrease visual acuity and floaters (Table 1). He denied ocular pain, fever, anorexia, and other systemic symptoms. BCVA in OD was 6/10 and in OS was 5/10. Biomicroscopic examination was unremarkable in both eyes. Dilated ocular fundus examination showed vitritis, vitreous haemorrhage, and extensive retinal venous vasculitis with haemorrhages in all retinal quadrants and macular edema (Figure 2). Fluorescein angiography showed bilateral severe occlusive venous vasculitis associated with paramacular, midperipheral, and peripheral retinal ischemia (Figure 3), and spectral domain optical coherence tomography (SD-OCT) revealed cystoid macular edema (CME) in both eyes (Table 1).

Investigation of the etiology included hemogram, inflammatory markers (C-reactive protein and erythrocyte sedimentation rate), human leukocyte antigen (HLA) B51, lysozyme, angiotensin-converting enzyme (ACE), infectious serologic testing and hemoglobin electrophoresis, coagulation, and prothrombotic evaluation that were all unremarkable, except for tuberculin skin sensitive test (20 mm) and IGRA (>10) which were positive. X-ray and CT scan of the thorax also revealed unspecific small bilateral hilar ganglia (Table 1).

Eales’ disease was suspected, and patient started complete quadruple antituberculosis treatment, which was maintained for nine months, associated with oral corticoid therapy (prednisolone 1 mg/Kg/day) with slow progressive withdrawal and subsequent introduction of oral methotrexate (20 mg/week) in order to achieve control of the disease. Serial treatment regime with anti-VEGF vitreous injections was also performed in both eyes (in a total of 11 in each eye). Laser photocoagulation was also required in both eyes over four sessions (Figure 2 and Table 1). This therapeutic approach allowed progressive clinical improvement.

After two years of follow-up, the patient maintains immunosuppression with oral methotrexate (20 mg/week) associated with prednisolone (2.5 mg/day) and achieved almost complete visual acuity recovery for 10/10 in both eyes, although with significant restriction of visual field, induced by both severe retinal ischemia and photocoagulation (Table 1).

2.3. Patient 3. A 58-year-old Caucasian male with known medical history of dyslipidemia, diabetes mellitus type 2 for 15 years, and ischemic stroke 15 years before presented to the emergency room with complaints of floaters in his left eye over the previous 6 months (Table 1). At presentation, BCVA was 8/10 OD and 5/10 OS. Anterior segment evaluation was unremarkable. Fundoscopy revealed peripheral retinal hemorrhages in both eyes and irregular macular reflex, inferior vitreous hemorrhage, vascular remodeling, and neovascularization in OS (Table 1). Fluorescein angiography showed retinal venous vasculitis with peripheral ischemia and neovascularization in both eyes, with no suggestive appearance of diabetic retinopathy (Figure 4). Patient also performed SD-OCT which revealed epiretinal membrane (ERM) with CME in the OS (Table 1).

Detailed clinical history and thorough systemic examination including serologic analysis, hemogram, inflammatory
markers, protein, and hemoglobin electrophoresis were unremarkable. X-ray and CT scan of the thorax evidenced pulmonary parenchyma with apical reticular pattern and residual fibrotic and retracted changes (Table 1). Once other causes of vasculitis and infections have been ruled out and tuberculin skin sensitive test (41 mm) and IGRA (2.77) were positive, Eales’ disease was considered.

Patient started a complete quadruple antituberculosis treatment associated with oral corticoid therapy (prednisolone 1 mg/Kg/day) with progressive withdrawal. Scatter laser photocoagulation and three anti-VEGF vitreous injections were also performed in both eyes (Table 1). Although poor patient’s compliance, clinical improvement with complete regression of vasculitis and neovascularization was achieved. Almost 4 years after diagnosis, patient remains clinically stable and had significant visual acuity recovery (BCVA was 10/10 OD and 8/10 OS), maintaining close follow-up and no need for treatment.

### 3. Discussion

Defined as a primary idiopathic disorder of peripheral retinal vessel, Eales’ disease pathophysiology is still poorly understood. This disease classically progresses in sequential stages involving retinal inflammation, occlusion, and neovascularization [2, 5]. Early inflammatory stage presents with retinal periphlebitis, which manifests as sheathing of blood vessels, primarily venous. This vasculitis leads to capillary occlusion in the middle stage which contributes to retinal ischemia with increased vascular endothelial growth factor [2]. Neovascularization seen at the boundaries between perfused and non-perfused zones of the retina is observed consequently in the late proliferative stage. It can happen up to 80% of the cases [1, 2], unlike disc neovascularization, which is rare [2]. Recently, it has been created a new 4 stage-grading classification in order to facilitate assess severity and functional prognosis of the disease [1, 2] (Table 2).

Eales is a bilateral condition in approximately 90% of patients. However, due to the inherent asymmetry, it can manifest itself unilaterally, as observed in patient 1, as sudden blurring of vision or floaters, caused by vitreous hemorrhage [1]. Sometimes, this presentation may difficult the correct diagnosis. In our case series, neovascularization associated with vitreous hemorrhages was present in patients 2 and 3. We speculated that in the first patient, the diagnosis was made sooner at an earlier stage, which allowed preventing this serious complication.

Immunologic mechanisms, mainly cell-mediated, have been proposed for Eales’ etiology [3, 5]. From the various causes suggested, *Mycobacterium tuberculosis* is the most common reported. Although the role of this antigen is not

| Stage | Description |
|-------|-------------|
| Ia | Periphlebitis of small caliber vessels with superficial retinal hemorrhages |
| Ib | Periphlebitis of large caliber vessels with superficial retinal hemorrhages |
| IIa | Capillary nonperfusion |
| IIb | Neovascularization elsewhere/of the disc |
| IIIa | Fibrovascular proliferation |
| IIIb | Vitreous hemorrhage |
| IVa | Traction/rhegmatogenous retinal detachment |
| IVb | Rubeosis iridis, neovascular glaucoma, complicated cataract, and optic atrophy |

---

**Figure 3:** Fluorescein angiography showing (a) retinal venous vasculitis, perivascular hemorrhages, and severe retinal ischemia in both eyes in patient 2 and (b) after treatment, including scatter laser photoocoagulation.

**Figure 4:** Fluorescein angiography showing significant occlusive vasculitis associated with peripheral ischemia, hemorrhages, and neovascularization in both eyes in patient 3.
completely determined, several studies propose that Eales disease is strongly related to both tuberculin protein hypersensitivity and previous exposure to tuberculosis [2, 5]. Indeed, the *Mycobacterium tuberculosis* genome had been detected through polymerase chain reaction studies in epiretinal membranes and vitreous samples of several Eales patients with tuberculin skin test positivity [6, 7].

In our case series, tuberculin skin sensitive test as well as IGRA test was positive in all patients, supporting the possible etiologic role of *Mycobacterium tuberculosis* in the pathogenesis of this entity and contributing to the diagnosis as well. However, the diagnosis of Eales’ disease requires exclusion of several other ocular or systemic inflammatory and noninflammatory diseases which can easily resemble its features [5]. Branch retinal vein occlusion, proliferative diabetic retinopathy, Coats disease, and sickle cell disease are all retinal entities which manifest with similar peripheral retinal nonperfusion that must be ruled out [1, 5]. It is also important to exclude systemic infections and noninfectious diseases such as syphilis, sarcoidosis, toxoplasmosis, systemic lupus erythematosus, or Behçet disease [5, 8]. As we reported with our case series a detailed clinical history, ocular and systemic examination with appropriate diagnostic testing, including serologic analysis, hemoglobin electrophoresis, tuberculin skin sensitive test, and/or IGRA is usually required and essential for a complete diagnosis approach.

Treatment approach is defined in accordance with the clinical stage of the disease. Systemic corticosteroids are the mainstay of treatment for active vasculitis, especially in severe bilateral cases [2]. Although the role of antituberculous therapy in Eales disease remains some point controversial, authors believe that its association with corticosteroids is extremely important in the disease control when IGRA and/or tuberculin sensitivity test are positive, or patients present with a presumably lung tubercular lesion [2, 8, 9]. In this way, all presented cases have been treated with the association of systemic corticosteroids and antituberculosis therapy, and two of them required immunosuppressive therapy with oral methotrexate as well, to achieve disease control and to prevent the adverse effects of corticosteroid treatment complications. In the proliferative stage, retinal photoacoagulation combined with anti-VEGF intravitreal injections is the treatment of choice [10]. In cases of macular edema, anti-VEGF intravitreal injections are also indicated [9, 11]. Retinal photoacoagulation was performed in all cases, and anti-VEGF intravitreal injections required in patients 2 and 3 for macular edema and/or associated neovascularization treatment. Photoacoagulation is not recommended in case of active vasculitis, as it may release more angiogenic factors, with potential worsening of neovascularization [5]. Previous treatment with corticosteroid or immunosuppressive therapy may avoid demand of subsequent photoacoagulation [5]. The major indication for pars plana vitrectomy is persistent vitreous hemorrhage and less commonly, tractional retinal detachment or ERM [5, 12]. Patient 3 developed ERM, although with no need for surgical treatment yet.

Although the progressive nature of this disease and the possible associated ocular complications such as tractional retinal detachment, neovascular glaucoma, ruberosis iridis, and cataract, visual prognosis is generally good. Recurrent vitreous hemorrhages are the most frequent cause of visual loss, which is transitory most of the time, as observed in our patients. Therefore, patients with Eales’ disease can have a hopeful prognosis, being mainly affected by early diagnosis, prompt treatment, and regular long-term follow-up.

Our case series intend to draw attention to this rare entity which has become more frequent in the western world and between older adults. In this way, clinical suspicious and knowledge of the appropriate therapeutic management of the disease are essential to prevent clinical progression and the onset of ocular complications, as we accomplished with our patients.

### Data Availability
Data are available within the article.

### Consent
Consent for publication was obtained from patients.

### Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this article.

### References

[1] J. Davis, S. H. Schecter, and J. Sowka, “Eales’ disease: the great masquerader,” *Optometry*, vol. 80, no. 7, pp. 354–359, 2009.

[2] J. Biswas, R. K. Ravi, A. Naryanasamy, L. T. Kulantai, and H. N. Madhavan, “Eales’ disease - current concepts in diagnosis and management,” *Journal of Ophthalmic Inflammation and Infection*, vol. 3, no. 1, p. 11, 2013.

[3] M. H. Errera, A. Pratas, P. Goldschmidt, N. Sedira, J. A. Sahel, and J. Benesty, “Eales’ disease,” *Journal Français d’Ophtalmologie*, vol. 39, no. 5, pp. 474–482, 2016.

[4] J. Biswas, T. Sharma, L. Gopal, H. N. Madhavan, K. N. Sulochana, and S. Ramakrishnan, “Eales disease—an update,” *Survey of Ophthalmology*, vol. 47, no. 3, pp. 197–214, 2002.

[5] P. Nanperumalsamy and D. Shukla, *Retina*, Elsevier, 5th edition, 2013.

[6] J. Biswas, L. Therese, and H. N. Madhavan, “Use of polymerase chain reaction in detection of *Mycobacterium tuberculosis* complex DNA from vitreous sample of Eales’ disease,” *British Journal of Ophthalmology*, vol. 83, no. 8, p. 994, 1999.

[7] H. N. Madhavan, K. L. Therese, P. Gunisha, U. Jayanthi, and L. Biswas, “Polymerase chain reaction for detection of *Mycobacterium tuberculosis* in epiretinal membrane in Eales’ disease,” *Investigative Ophthalmology and Visual Science*, vol. 41, no. 3, pp. 822–825, 2000.

[8] D. Călugăru, M. Călugăru, and C. el Ghali, “Eales disease in a young adult man Case report,” *Romanian Journal of Ophthalmology*, vol. 61, no. 4, pp. 306–309, 2017.

[9] T. Das, A. Pathengay, N. Hussain, and J. Biswas, “Eales’ disease: diagnosis and management,” *Eye*, vol. 24, no. 3, pp. 472–482, 2010.

[10] S. D. Patwardhan, R. Azad, B. M. Shah, and Y. Sharma, “Role of intravitreal bevacizumab in Eales disease with dense
vitreous hemorrhage: a prospective randomized control study,” Retina, vol. 31, no. 5, pp. 866–870, 2011.

[11] S. R. Gupta and C. J. Flaxel, “The use of a vascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease,” Retinal Cases & Brief Reports, vol. 6, no. 1, pp. 122–124, 2012.

[12] A. M. A. el-Asrar and S. A. al-Kharashi, “Full panretinal photocoagulation and early vitrectomy improve prognosis of retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales’ disease),” The British Journal of Ophthalmology, vol. 86, no. 11, pp. 1248–1251, 2002.

[13] S. Saxena and D. Kumar, “A new staging system for idiopathic retinal periphlebitis,” European Journal of Ophthalmology, vol. 14, no. 3, pp. 236–239, 2004.